Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.41 |
| ▸ | GCG | P01275 | 11/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3397932 | 0.90 | GCG (0.48) | RCE1GCGSMN1; SMN2 | |
| SCHEMBL720811 | 0.87 | MEN1 (0.48) | MEN1KMT2AGCGMAPTCYP1A2 | |
| SCHEMBL719205 | 0.87 | MEN1 (0.48) | MEN1KMT2AGCGKDM4ESMN1; SMN2 | |
| SCHEMBL721580 | 0.86 | RCE1 (0.40) | MEN1KMT2ARCE1KDM4EL3MBTL1 | |
| SCHEMBL719091 | 0.85 | MEN1 (0.46) | MEN1KMT2AGCGL3MBTL1CYP1A2 | |
| SCHEMBL718024 | 0.84 | GCG (0.43) | RCE1GCG | |
| SCHEMBL719072 | 0.83 | MEN1 (0.42) | MEN1KMT2ARCE1GCGMAPT | |
| SCHEMBL719578 | 0.83 | MEN1 (0.48) | MEN1KMT2AGCGKDM4ECYP1A2 | |
| SCHEMBL717537 | 0.82 | RCE1 (0.48) | MEN1KMT2ARCE1SMN1; SMN2CYP1A2 | |
| SCHEMBL720334 | 0.82 | RCE1 (0.59) | RCE1KDM4ECYP1A2HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8436043-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-05-07 | — | — | US | disclosed |
| US-20120270865-A2 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-10-25 | — | — | US | disclosed |
| US-20120053173-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-03-01 | — | — | US | disclosed |
| EP-2251326-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2010-11-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120053173-A1 | HETEROCYCLIC COMPOUND | SLC5A2, SLC5A1, IAPP | MEN1 444/4885KMT2A 1298/4885RCE1 2661/4885 |
| US-20120270865-A2 | HETEROCYCLIC COMPOUND | SLC5A2, SLC5A1, IAPP | MEN1 444/4885KMT2A 1298/4885RCE1 2661/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.